ASCO Resets Stage For Third-Generation EGFR Contest: May Come Down To Safety Or Resistance
Executive Summary
To some market observers, latest round of data for new EGFR inhibitors presented at the ASCO meeting gives AstraZeneca an edge on efficacy over close competitor Clovis, but differences in trial designs make it hard to compare efficacy at this time.